MA50864A - Formulation à base de n-acétylcystéine et d'urée pour le traitement de troubles dermatologiques - Google Patents

Formulation à base de n-acétylcystéine et d'urée pour le traitement de troubles dermatologiques

Info

Publication number
MA50864A
MA50864A MA050864A MA50864A MA50864A MA 50864 A MA50864 A MA 50864A MA 050864 A MA050864 A MA 050864A MA 50864 A MA50864 A MA 50864A MA 50864 A MA50864 A MA 50864A
Authority
MA
Morocco
Prior art keywords
acetylcystein
urea
treatment
formulation based
dermatological disorders
Prior art date
Application number
MA050864A
Other languages
English (en)
Inventor
Alessandro Calderan
Original Assignee
Alessandro Calderan
Dermalena Di Calderan Andrea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alessandro Calderan, Dermalena Di Calderan Andrea filed Critical Alessandro Calderan
Publication of MA50864A publication Critical patent/MA50864A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/17Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16Cyclodextrin; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MA050864A 2017-11-06 2018-10-29 Formulation à base de n-acétylcystéine et d'urée pour le traitement de troubles dermatologiques MA50864A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT201700125963 2017-11-06

Publications (1)

Publication Number Publication Date
MA50864A true MA50864A (fr) 2020-09-16

Family

ID=61527092

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050864A MA50864A (fr) 2017-11-06 2018-10-29 Formulation à base de n-acétylcystéine et d'urée pour le traitement de troubles dermatologiques

Country Status (5)

Country Link
US (1) US20210052524A1 (fr)
EP (1) EP3706714B1 (fr)
ES (1) ES2932359T3 (fr)
MA (1) MA50864A (fr)
WO (1) WO2019086366A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU231668B1 (hu) * 2021-12-28 2025-06-28 Semmelweis Egyetem 60% Szemcsepp készítmény

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733535A (en) 1995-10-25 1998-03-31 The Procter & Gamble Co. Topical compositions containing N-acetylcysteine and odor masking materials
US6149925A (en) * 1998-11-05 2000-11-21 Color Access, Inc. Topical compositions for enhancing glutathione production
US20030229141A1 (en) 1999-01-08 2003-12-11 Yu Ruey J. N-acetyl cysteine and its topical use
US20030138466A1 (en) * 2001-11-28 2003-07-24 Bradley Pharmaceuticals, Inc. Antioxidant dermatological composition
ATE352204T1 (de) * 2002-08-20 2007-02-15 Lonza Ag Stabile synergistische antimikrobielle zusammensetzungen aus aldehyddonatoren und deshydroessigsüure mit niedrigem gehalt an freiem formaldehyd
US7556819B1 (en) * 2003-07-25 2009-07-07 Opi Products, Inc. Skin composition
US20110044920A1 (en) * 2009-08-07 2011-02-24 Mary Kay Inc. Topical skin care formulations
EP2397125A1 (fr) 2010-06-15 2011-12-21 Histocell, S.L. Composition antioxydante
EP2846769A1 (fr) * 2012-05-11 2015-03-18 Cipla Limited Composition pharmaceutique
CN104225583B (zh) * 2014-09-03 2016-09-28 苏州瑞派尔生物科技有限公司 一种用于皮肤损伤修复的组合物
US20160338993A1 (en) 2015-05-21 2016-11-24 The Regents Of The University Of California Wound healing

Also Published As

Publication number Publication date
EP3706714A1 (fr) 2020-09-16
ES2932359T3 (es) 2023-01-18
WO2019086366A1 (fr) 2019-05-09
US20210052524A1 (en) 2021-02-25
EP3706714B1 (fr) 2022-09-14

Similar Documents

Publication Publication Date Title
EP3484577A4 (fr) Procédés et systèmes de traitement de troubles pelviens et d&#39;affections douloureuses
EP3448389A4 (fr) Composés de quinazoline et d&#39;indole destinés au traitement de troubles médicaux
MA50417A (fr) Procédés d&#39;utilisation d&#39;inhibiteurs de l&#39;ehmt2 dans le traitement ou la prévention de troubles du sang
MA49279A (fr) Compositions d&#39;anticorps optimisées pour le traitement de troubles oculaires
EP3448398A4 (fr) Compositions et méthodes pour le traitement de troubles cutanés
EP3758664A4 (fr) Dispositif portatif doté d&#39;un élément vibratoire pour le traitement de troubles
EP3481387A4 (fr) Methodes et compositions pour le traitement de troubles épileptiques
EP3704108A4 (fr) Composés et compositions pour le traitement de troubles hématologiques
EP3630102A4 (fr) Formulations pour le traitement d&#39;un trouble de stress post-traumatique
MA50155A (fr) Acides aminés à chaîne ramifiée pour le traitement d&#39;une lésion neuronale
EP3466447A4 (fr) Composition pharmaceutique à usage externe indiquée pour le traitement d&#39;ulcères cutanées multiples
EP3606520A4 (fr) Inhibiteurs de l&#39;activité de la déshydrogénase à chaîne courte pour le traitement des troubles coronaires
EP3512517A4 (fr) Utilisation de pridopidine pour le traitement de l&#39;anxiété et de la dépression
PT3405215T (pt) Métodos para o tratamento da doença de danon e outros transtornos da autofagia
EP3938340A4 (fr) Dérivés aromatiques hétérobicycliques et hétéroaromatiques pour le traitement de troubles liés à la ferroptose
MA51056A (fr) Compositions et méthodes pour le traitement d&#39;affections métaboliques
EP3801489A4 (fr) Agents actifs acylés et leurs procédés d&#39;utilisation pour le traitement de troubles auto-immuns
EP3672587A4 (fr) Compositions pharmaceutiques destinées au traitement d&#39;affections ophtalmiques
MA49794A (fr) Composition utilisée dans le traitement prophylactique et thérapeutique de troubles de l&#39;appareil cardiovasculaire
IL282562A (en) Composition and use for the treatment of parkinson&#39;s disease and related disorders
MA49524A (fr) Compositions d&#39;antagoniste de nk-1 et méthodes destinées à être utilisées dans le traitement de la dépression
EP3348643A4 (fr) Interleukine 12 modifiée et utilisation de celle-ci dans la préparation de médicaments pour le traitement de tumeurs
MA43825A (fr) Schémas posologiques pour le traitement d&#39;infections fongiques
EP3654961A4 (fr) Méthodes et compositions pour le traitement de la douleur à l&#39;aide de la capsaïcine
EP3398614A4 (fr) Agent pour la prévention et/ou le traitement de la maladie d&#39;alzheimer